Skip to main content
. Author manuscript; available in PMC: 2020 Apr 15.
Published in final edited form as: J Neurol Sci. 2019 Feb 7;399:22–29. doi: 10.1016/j.jns.2019.02.013

Table 1.

Demographics and disease characteristics

Weak (n=7) Typical (n=30) Weak-Visuospatial/Strong-Memory (n=9) Weak-Visuospatial (n=21) Amnestic (n=26) Strong (n=29) Statistical comparison
Age 66.29 (7.65) 65.43 (4.78) 59.89 (9.2) 63.43 (8.15) 64.81 (6.74) 61.14 (7.12) F(5, 116)=2.039, p=.078
Gender, male (%) 100 76.7 44.4 66.7 80.8 69 χ2(5)=7.971, p=.158
Years of education 13 (3.32) 14.7 (2.22) 15 (1.87) 15.24 (2.59) 14.73 (2.95) 15.9 (2.5) F(5,110)=1.506, p=.194
Handedness, right (%) 71.4 93.3 77.8 85.7 88.5 86.2 χ2(5)=13.229, p=.211
Family history of PD (%) 28.6 16.7 11.1 19 30.8 17.2 χ2(5)=2.937, p=.710
APOEe4 carrier (%) 28.6 26.7 44.4 28.6 26.9 6.9 χ2(5)=10.420, p=.404
Disease duration, months 7.17 (8.28) 4.86 (4.74) 5.25 (6.23) 7.81 (6.96) 9.27 (8.19) 5.42 (7.42) F(5,110)=1.487, p=.200
Dominantly affected side, right (%) 14.3 33.3 22.2 52.4 38.5 41.4 χ2(5)=11.177, p=.344
HYS, 1 (%) 33.3 44.8 37.5 28.6 23.1 61.5 χ2(5)=9.707, p=.084
MDS-UPDRS total score 39.83 (16.87) 30.72 (13.76) 29.88 (11) 35.38 (14.51) 34.08 (12.1) 28.35 (11.86) F(5, 110)=1.330, p=.257
MDS-UPDRS Part I 2.67 (2.16) 0.93 (1.07) 1.88 (1.81) 1.05 (1.2) 1.58 (1.98) 0.77 (0.99) F(5,100)=2.643, p=.027*
MDS-UPDRS Part I Patient Questionnaire 5 (4.24) 4 (3.93) 3.88 (3.09) 3.95 (2.82) 5.08 (3.15) 4.5 (2.92) F(5,110)=.462, p=.804
MDS-UPDRS Part II 6.33 (3.56) 4.69 (3.89) 5.5 (4) 5.91 (4.17) 5.65 (4.05) 5.65 (3.42) F(5,110)=.462, p=.867
MDS-UPDRS Part III 25.83 (10.94) 21.1 (9.32) 18.63 (5.76) 24.48 (8.89) 21.77 (8.8) 17.42 (7.85) F(5,110)=2.079, p=.073
MoCA 26.29 (2.5) 27.47 (1.96) 28.44 (1.59) 26.48 (2.54) 26 (2.62) 27.59 (2.04) F(5,116)=2.788, p=.020*

PD: Parkinson’s Disease Rating Scale; MoCA: Montreal Cognitive Assessment.

All variables are stated as mean (standard deviation) or percentage where applicable.

Statistical significance is marked with *.